GRAIL, Inc.'s stock plummeted 47.50% in pre-market trading on Friday, following a significant decline in after-hours activity the previous session.

The sharp drop came after the company announced that its landmark NHS-Galleri trial for the Galleri multi-cancer early detection test failed to meet its primary endpoint. The trial did not achieve a statistically significant reduction in combined Stage III and Stage IV cancer diagnoses, representing a major setback for the company's flagship product.

While the trial demonstrated positive secondary outcomes, including a reduction in Stage IV cancer diagnoses and increased early-stage detection, the failure to hit the main statistical goal has raised concerns about regulatory pathways and commercial timelines, leading to a severe investor reaction.